Navigation Links
Sunridge to Introduce Their PNT Treatment for Glaucoma to Medical Personnel in India
Date:9/28/2010

FOUNTAIN HILLS, Ariz., Sept. 28 /PRNewswire/ -- Sunridge International (OTC Bulletin Board: SNDZ) said today that their treatment for glaucoma and ocular hypertension will be introduced in October to eye doctors and the medical community in India.

Presentations have been planned by its Indian distributors, New Amsterdam Marketing Corporation, in major cities from October 1 – 14.  The company's Pneumatic Trabeculoplasty (PNT), treatment is a cost-effective, non-invasive procedure designed to reduce pressure on the retinal nerve. The two-minute procedure, easily performed in a clinic or doctors office, is required only three or four times a year. It is a treatment regime that is especially valuable to patients in rural areas, where traditional medical facilities are limited.

Sunridge International, the developer and marketer of the PNT treatment, announced today that it's exclusive marketer in India, will be holding meetings to demonstrate the procedure to hundreds of medical personnel throughout the country.

The first presentations will be held at the (www.apos.in) conference in Hyderabad from October 1-3. This will be followed by meetings in Calcutta, Mumbai and Jaipur. The presentations will be led by Dr. Leo Bores, M.D.  Dr. Bores also will be holding private meetings over a two week period in India.

G. Richard Smith, CEO of Sunridge International, said the company was especially pleased to be able to bring the PNT procedure to India. "We are introducing our PNT equipment and treatments in many markets throughout the world, including the European Union countries, China and Latin America. But India is a very special place. It offers enormous opportunity for us."

"Working with New Amsterdam colleagues, we look forward to helping, perhaps, thousands of people suffering from glaucoma and ocular hypertension throughout the country. Often in the rural countryside, with a very poor population, glaucoma is left untreated. For many the cost of ongoing treatment is simply out of their reach. We strongly believe that PNT provides an answer to this problem, and gives people an opportunity for a safe, effective and affordable treatment.

"We will be giving the doctors and medical personnel attending the New Amsterdam presentations our fullest support and look forward to a long and mutually rewarding association with them."

Glaucoma is the second leading cause of blindness, affecting more than 70 million people worldwide. Studies completed over the last 10 years have proven that PNT is a safe effective and cost effective alternative treatment for glaucoma and ocular hypertension. The two-minute treatment has been developed, patented and distributed by Sunridge International's wholly-owned subsidiary, Ophthalmic International.(www.oi-pnt.com).CONTACT:Jeff Smith, Sunridge International   T:  +1-480-837-6165e-mail: info@sunridgeint.com website: www.sunridgeint.com MEDIA:Victor Webb, Marston Webb InternationalT: (212) 684-6601e-mail: marwebint@cs.com
'/>"/>

SOURCE Sunridge International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunridge Announces Marketing Roll Out of PNT in the Dominican Republic
2. Sunridge Schedules European Meetings
3. Sunridge Ships First Order to the Middle East
4. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
5. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
6. Dr. Dello Russo Introduces the New EYE-Q Lasik
7. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
8. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
9. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
10. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Ethicon* today ... Medical, Inc., a privately held medical device company ... System for the surgical treatment of Gastroesophageal Reflux ... strategy of expanding its portfolio of minimally invasive ... medical conditions. Financial terms of the transaction have ...
(Date:3/23/2017)... , March 23, 2017 CENTRO DE ... article 157, paragraph 4 of Law 6,404/76 and Instruction ... hereby informs its shareholders and the market in general ... its subsidiary Centro de Diagnosticos por Imagem Ltda. (" ... 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " ...
(Date:3/23/2017)... 23, 2017  A new genetic test has ... of individuals who carry HLA-B*15:02 and ... yet potentially deadly side effect of certain medications ... gene HLA-B*15:02 is strongly associated with ... syndrome and toxic epidermal necrolysis in patients treated ...
Breaking Medicine Technology:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... of SmartBen NOW, an innovative mobile app and centralized benefits dashboard solving one ... critical information securely from multiple locations. For the first time, employees can access ...
(Date:3/23/2017)... ... March 23, 2017 , ... The TouchPoint Solution, home ... world to manage stress and anxiety. , “Buzzies change the way we interact ... co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint Solution ...
(Date:3/23/2017)... ... 23, 2017 , ... Altec Products, Inc. , a ... their 2016 Microsoft Dynamics Partner of the Year at DocLink Evolution , ... recognizes The Resource Group for their outstanding relationship with Altec and their ability ...
(Date:3/23/2017)... ... March 23, 2017 , ... According to the National ... sleep is likely not the only cause of the sunken-eye look, which can include ... look older or in poor health are likely due to genetics, dehydration, allergies, and ...
(Date:3/23/2017)... El Segundo, CA (PRWEB) , ... March 23, ... ... Verisys FACIS Monthly Monitoring Healthcare products at competitive pricing. ... primary source sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are ...
Breaking Medicine News(10 mins):